Lyell Immunopharma (LYEL) EPS (Weighted Average and Diluted) (2020 - 2025)
Lyell Immunopharma (LYEL) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$7.68 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 46.67% to -$7.68 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.88 through Dec 2025, up 40.67% year-over-year, with the annual reading at -$16.06 for FY2025, 38.77% up from the prior year.
- EPS (Weighted Average and Diluted) hit -$7.68 in Q4 2025 for Lyell Immunopharma, down from -$2.13 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.03 in Q4 2022 to a low of -$17.97 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$2.95 across 5 years, with a median of -$0.28 in 2022.
- Biggest five-year swings in EPS (Weighted Average and Diluted): soared 93.87% in 2021 and later plummeted 59800.0% in 2023.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.18 in 2021, then surged by 83.33% to -$0.03 in 2022, then tumbled by 59800.0% to -$17.97 in 2023, then grew by 19.87% to -$14.4 in 2024, then skyrocketed by 46.67% to -$7.68 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for LYEL at -$7.68 in Q4 2025, -$2.13 in Q3 2025, and -$2.89 in Q2 2025.